Expression of mutant C2GnT-I does not confer galectin-1 susceptibility. (A) Cells expressing WT clone 6 or mut clone 2 enzyme (from Figure 5A) were analyzed for annexin V binding after treatment with galectin-1 (dark line) and compared with annexin V binding of cells transfected with vector alone after treatment with galectin-1 (dotted line). (B) Cell death determined by annexin V binding and propidium iodide uptake of BW5147 cells transfected with vector alone, WT C2GnT-I (WT clone 6), or mutant C2GnT-I (mut clone 2). PhaR2.1 cells that express endogenous C2GnT and are susceptible to galectin-1 were used as a positive control. *P < .001 for cells expressing WT C2GnT-I compared with vector or mutant C2GnT-I. Values are mean ± SD of triplicates from 1 of 3 independent experiments.